(Albany, New York) – 21st Sep 2026 – DelveInsight’s latest report, “Glioma Market Insight, Epidemiology and Market Forecast – 2036,” provides a comprehensive assessment of the global Glioma treatment market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report evaluates historical and forecasted epidemiology, patient burden, treatment practices, market dynamics, marketed and emerging therapies, competitive intelligence, drug uptake, reimbursement, unmet needs, and future market opportunities through 2036.
According to DelveInsight, the Glioma treatment market across the 7MM was valued at over USD 1 billion in 2025 and is projected to grow at approximately 15% CAGR during 2022–2036. The United States accounted for the largest share of the Glioma market in 2025, representing approximately 65% of the total market.
Key Takeaways from the Glioma Market
Keen to know more about the Glioma market? Request a sample copy of the report for detailed market insights, epidemiology, treatment patterns, competitive intelligence, and forecast analysis. https://www.delveinsight.com/sample-request/glioma-market
Key Factors Driving the Glioma Market
Rising Glioma Prevalence
The increasing incidence and prevalence of glioma, particularly aggressive forms such as glioblastoma, remain important factors supporting market growth. Although glioma is a relatively rare cancer, its high mortality and recurrence rates create a sustained population requiring ongoing treatment and disease management.
Improved diagnostic capabilities and an aging population are also contributing to the identification and management of glioma cases across major markets.
Advancements in Treatment Approaches
The glioma treatment landscape has evolved beyond conventional surgery, radiation, and chemotherapy. The introduction of tumor treating fields, targeted therapies, immunotherapies, cancer vaccines, and oncolytic viruses is broadening treatment options for patients with different molecular and clinical characteristics.
The emergence of biomarker-driven therapies is particularly important in low-grade and molecularly defined gliomas.
Growing Opportunities in Precision Medicine
Precision medicine is increasingly shaping glioma treatment. Therapies targeting specific genetic alterations, including IDH mutations, BRAF V600E mutations, and H3 K27M mutations, are expanding treatment options for molecularly selected populations.
VORANIGO (vorasidenib) for IDH-mutant Grade 2 astrocytoma and oligodendroglioma and MODEYSO (dordaviprone) for H3 K27M-mutant diffuse midline glioma illustrate the movement toward biomarker-defined treatment.
Expansion of Immunotherapy and Cancer Vaccines
Cancer vaccines and cell-based immunotherapies represent an important segment of the emerging glioma pipeline. Candidates such as DCVax-L, AV-GBM-1, SurVaxM, and ITI-1000 are being investigated for their potential to generate durable antitumor immune responses.
These approaches are particularly relevant because conventional therapies continue to provide limited long-term disease control in high-grade glioma.
Development of Oncolytic Virus Therapies
Oncolytic viruses are another growing area of innovation. DELYTACT (teserpaturev), DNX-2401, and Ofranergene Obadenovec are designed to exploit tumor-specific biology while stimulating an antitumor immune response.
The continued development of these approaches could broaden therapeutic options for patients with recurrent or treatment-resistant disease.
Competitive Landscape
The Glioma market consists of established therapies alongside a diverse pipeline of targeted agents, immunotherapies, cancer vaccines, oncolytic viruses, and novel drug-delivery approaches.
Key companies include:
The marketed landscape includes TEMODAR, AVASTIN, OPTUNE, TAFINLAR + MEKINIST, VORANIGO, and DELYTACT, while the emerging pipeline includes DCVax-L, AV-GBM-1, Enzastaurin, Paxalisib, LAM561, SurVaxM, DNX-2401, ITI-1000, and Berubicin.
Recent Developments in the Glioma Market
What is Glioma?
Glioma is the most common central nervous system (CNS) neoplasm and originates from glial cells. These tumors are often diffusely infiltrative and can affect surrounding brain tissue. Common glioma types include astrocytomas, ependymomas, and oligodendrogliomas.
Gliomas are classified into Grades I–IV based on their biological and histological characteristics. Glioblastoma (Grade IV) represents the most aggressive form, while Grade I tumors such as pilocytic astrocytomas are generally less malignant.
Genetic alterations play an important role in glioma development and classification. Important genes and molecular alterations include TP53, PTEN, BRAF, and IDH1, among others. Molecular characterization is increasingly important for diagnosis, prognosis, and treatment selection.
Diagnosis of Glioma
Glioma diagnosis generally begins with neurological evaluation and imaging. Common diagnostic approaches include:
MRI is an important imaging modality because it provides detailed visualization of brain structures and assists in differentiating brain tumors. When imaging suggests glioma, biopsy and molecular analysis can help establish tumor type and grade and guide treatment selection.
Current Treatment Landscape
Glioma treatment depends on the tumor type, grade, molecular characteristics, location, size, and patient-specific factors. The standard treatment approach generally involves maximum safe surgical resection followed by radiation therapy and chemotherapy when clinically appropriate.
Temozolomide (TEMODAR)
Temozolomide remains a cornerstone of glioma treatment, particularly for glioblastoma. It is an oral alkylating agent that crosses the blood–brain barrier and damages tumor-cell DNA. It is commonly used with radiation therapy in newly diagnosed glioblastoma and as maintenance therapy.
Bevacizumab (AVASTIN)
Bevacizumab is a VEGF inhibitor that suppresses tumor angiogenesis. It remains an important treatment option, particularly in recurrent glioma, although its effect on overall survival remains limited.
OPTUNE
OPTUNE is a tumor treating fields device that uses alternating electrical fields to interfere with tumor-cell division. It is used alongside chemotherapy in eligible patients and has become an important component of glioblastoma treatment.
TAFINLAR + MEKINIST
The combination of dabrafenib (TAFINLAR) and trametinib (MEKINIST) targets the MAPK pathway and is used for BRAF V600E-mutant gliomas. Its availability represents an important advancement in biomarker-driven treatment.
VORANIGO (Vorasidenib)
Vorasidenib is a brain-penetrant inhibitor targeting mutant IDH1 and IDH2. The US FDA approved VORANIGO in August 2024 for patients aged 12 years and older with Grade 2 astrocytoma or oligodendroglioma harboring susceptible IDH1 or IDH2 mutations following surgery.
MODEYSO (Dordaviprone)
Dordaviprone received accelerated FDA approval in August 2025 for adult and pediatric patients aged 1 year and older with H3 K27M-mutant diffuse midline glioma with progressive disease following prior therapy. It represents a targeted treatment option for this molecularly defined, aggressive tumor.
Glioma Epidemiology
According to DelveInsight’s estimates, Glioma incident cases across the 7MM were approximately 51,000 in 2025. The epidemiological analysis evaluates total incident cases as well as grade-, age-, and type-specific disease burden across the seven major markets.
Key epidemiological findings include:
Epidemiology Segmentation
DelveInsight segments Glioma epidemiology into:
Unmet Needs in Glioma
Despite significant advances in diagnosis and treatment, important unmet needs remain:
These challenges are driving research into precision medicine, immunotherapy, cancer vaccines, oncolytic viruses, novel drug-delivery platforms, and combination treatment strategies.
Scope of the Glioma Market Report
To Know More About the Glioma Market Report
Glioma Market Insight, Epidemiology and Market Forecast – 2036
Table of Contents
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
